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Abstract
Background: Reports on the clinical meaningfulness of outcome measures in spinal muscular atrophy (SMA) are
rare. In this two-part study, our aim was to explore patients’ and caregivers’ views on the clinical relevance of the
Hammersmith Functional Motor Scale Expanded- (HFMSE).
Methods: First, we used focus groups including SMA patients and caregivers to explore their views on the clinical
relevance of the individual activities included in the HFMSE. Then we asked caregivers to comment on the clinical
relevance of possible changes of HFMSE scores over time. As functional data of individual patients were available,
some of the questions were tailored according to their functional level on the HFMSE.
Results: Part 1: Sixty-three individuals participated in the focus groups. This included 30 caregivers, 25 patients and
8 professionals who facilitated the discussion.
The caregivers provided a comparison to activities of daily living for each of the HFMSE items.
Part 2: One hundred and forty-nine caregivers agreed to complete the questionnaire: in response to a general
question, 72% of the caregivers would consider taking part in a clinical trial if the treatment was expected to slow
down deterioration, 88% if it would stop deterioration and 97% if the treatment was expected to produce an
improvement.
Caregivers were informed of the first three items that their child could not achieve on the HFMSE. In response 75%
indicated a willingness to take part in a clinical trial if they could achieve at least one of these abilities, 89% if they
could achieve two, and 100% if they could achieve more than 2.
Conclusions: Our findings support the use of the HFMSE as a key outcome measure in SMA clinical trials because
the individual items and the detected changes have clear content validity and clinical meaningfulness for patients
and their caregivers.
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Background
Several efforts have been made recently to identify disease
specific outcome measures for spinal muscular atrophy
(SMA) patients. The Hammersmith Functional Motor
Scale Expanded (HFMSE), a motor function scale specific-
ally designed for SMA, is widely used in patients. [1–3]
The activities included in the original Hammersmith scale
and in the expanded version were chosen by clinicians
because of their functional relevance after careful observa-
tion and evaluation of many SMA patients [1–3].
The potential for therapeutic benefit from interven-
tions in SMA has highlighted the need to obtain reliable
documented evidence of patient input to support the
clinical meaningfulness of the measures used in natural
history studies and in clinical trials [4–7].
The activities included in the HFMSE have been found
to be extremely useful in clinical practice as an assess-
ment and rehabilitation tool, and in natural history
studies and clinical trials to establish disease progression
[8–15]. However, no systematic study has been per-
formed to determine if the individual activities included
in the scale are also relevant for patients and their
caregivers.
This approach, to include the patient perspective, has
been strongly encouraged by the United States Food and
Drug Administration (FDA) [16]. This regulatory agency
has indeed suggested that patient reported scales should
be used to determine the relevance of the observed func-
tional changes [17].
One of the challenges is that SMA is clinically very
heterogeneous; and, even when restricted to the type 2
and 3 phenotypes whose functional domains are covered
by the HFMSE, the clinical severity still ranges from
non-ambulant sitting patients with only a few points on
the scale to ambulant patients who may be able to
complete nearly all of the 33 items on the scale [8, 9].
Another significant challenge is the variability of SMA
types 2 and 3 disease progression, as reported by recent
natural history studies, and the various factors, such as age
or functional level, that influence different trajectories [10].
Because of these and other challenges, it is may be
difficult to determine a clinically meaningful change for
patients at different ages and at different functional
levels. Moreover, it is not clear if similar quantitative
improvements in the scale, two points for example, have
the same clinical meaning regardless of where the pa-
tients score on the HFMSE scale.
This paper describes a two part study reporting: (1)
patients’ and caregivers’ view on the clinical relevance of
the HFMSE, and (2) the possible changes of HFMSE
scores over time. More specifically, in the first part we
aimed to explore caregivers’ and patients’ views on the
clinical meaningfulness of each individual HFMSE item,
asking them to describe the implications between the
activity being explored in the individual items and the
consequences as it relates to activities of daily living. In
the second part we collected caregivers’ views on the
relevance of possible changes on the HFMSE scale. The
novelty of our approach was that, rather than just asking
general open questions, we tailored them according to
each participant’s specific functional level based on their
HFMSE score.
Methods
Part 1: Content validity of the HFMSE
The first part was based on patients’ and caregivers’
focus groups as we explored content validity of individ-
ual HFMSE items. This qualitative study was conducted
in Italy between June and October 2015 as part of a
collaborative project with the two main Italian SMA ad-
vocacy groups (Famiglie SMA and Asamsi). The study
was approved by the Ethical Committees of all the par-
ticipating centers (Catholic University, Rome; University
of Messina, Messina; UCL Institute of Child Health &
Great Ormond Street Hospital, London; Columbia
University Medical Center, New York; Harvard Medical
School, Boston; Newcastle University, Newcastle; Stanford
University; University of Central Florida College of
Medicine, Orlando). Four focus groups were completed
during the annual conventions of both advocacy groups.
Three of the 4 focus groups included caregivers and
one also included patients. The participants volun-
teered to be part of these activities and signed a dedi-
cated consent form. No compensation was provided
for their participation.
Patients and caregivers were given a form describing
the items of the HFMSE, in lay language, illustrating the
activities included in the scale with some pictures. They
were then asked to comment on the relevance of the in-
dividual items, whether each activity assessed in the
items could be related to activities of daily living, and if
and why this was relevant to them.
Each focus group was run by a psychologist and a
member of our team (clinician or Physical therapist)
who transcribed the responses immediately before mov-
ing to the next item.
The results of the various groups were analyzed by
assigning a code to each response and by identifying con-
sistencies across the various groups tabulating the fre-
quency of individual responses in the various subgroups.
Part 2: Clinical meaningfulness of HFMSE changes
The aim for this part was to establish the view of the
caregivers on the clinical relevance of HFMSE changes
in relation to their children’s functional level. This could
only be performed in patients who had a recent clinical
functional assessment. This study was part of an inter-
national effort.
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From September 2015 to April 2016, we administered
a questionnaire or conducted semi-structured telephone
interviews with caregivers of type 2 and 3 SMA patients.
All consecutive patients attending our clinics, who rou-
tinely underwent functional assessments, were included.
Telephone interviews were only conducted if patients had
been seen within the previous 3 months and if the results
of their functional assessments were available.
All centers shared the same training and had already
performed inter-observer reliability for the HFMSE [10].
Study participants did not receive any form of compen-
sation. Caregivers were first asked to provide general
information regarding the patients’ disease course over
the last year and their expectations for the near future.
An innovative aspect of this questionnaire was the
introduction of specific questions that were related to
the subjects’ motor performance as assessed by the stan-
dardized HFMSE functional scale. In the scale the items
follow a hierarchical order with increasing difficulty,
from top to bottom, built on the frequency distribution
of findings observed in a large cohort of SMA patients
The score on the scale provides a clear indication of the
patient’s functional level, and the subsequent activities
represent activities likely to be achieved.
The advantage of this approach is that caregivers are
asked questions about activities that are realistically
close to their child’s possible achievements, rather than
generic questions on other activities, such as walking or
running for non-ambulant type 2 SMA patients, that
clearly would be highly desirable but difficult or impos-
sible to achieve in a limited time frame.
The first two questions evaluated the caregiver’s im-
pression of the patient’s overall function during the past
year, and their expectations for the next two years (see
appendix for details of the questionnaire).
The second set of questions included open-ended in-
quiries that were, according to the caregivers, the most
important activities/functions of daily living that they
hoped would be maintained or gained in their children.
Caregivers were finally asked to provide information
on their expectations regarding clinical trials.
They were informed on the next three items that their
child could not achieve on the HFMSE scale, asking
more specifically, if achieving at least one of these abil-
ities would justify their participation in a clinical trial.
The last question enquired whether the caregivers
would consider having their child take part in a
potential trial in the presence of mild side-effects. A
trained clinician conducted the in-person interviews
and telephone interviews using a semi-structured data
collection sheet. The interviews lasted 15-20 min on
average. The questions covered caregivers’ views and
expectations regarding a possible participation in a
clinical trial.
Statistical Analysis: Responses of the non-ambulant
and ambulant groups were compared for significant
difference using the Wilcoxon-Mann-Whitney test. A
p value of <0.05 was considered significant.
For the question assessing whether parents would con-
sider entering in a study if their child could achive at
least 1 (score0), two (score 1) or more than 2 activities
on the HFMSE, a Chi-square analysis was used to was
used to correlate the level of responses (0, 1, 2) with
functional scores. A p value of <0.05 was considered
significant.
Results
Part 1: Content validity
Sixty-three individuals participated in the focus groups.
These included 30 caregivers and 25 patients. Eight
professionals (psychologists, Physical Therapists or clini-
cians) conducted the interviews and facilitated the dis-
cussion by introducing the items without contributing to
data collection in an effort to avoid bias.
Patient ages ranged from 14 to 35 years, 3 were ambu-
lant and 22 non ambulant (20 type 2 and 2 type 3).
The caregivers were all parents (17 mothers and 13
fathers). The age of the patients represented by the care-
givers ranged between 2 and 26 years, 5 were ambulant
and 25 non ambulant (all type 2). Only one parent/care-
giver was allowed to participate for each patient.
The caregivers commented on all the functional scale
items and provided a comparison to activities of daily living
for each of them. Table 1 shows the responses in the 4 focus
groups illustrating whether some responses were reported in
more than one focus group. Many activities (64.07%) were
suggested by more than one group with only 37 of the 103
activities suggested by one group only. Of these 37, only 7
were suggested by the group including patients.
Part 2
One hundred-forty-nine of the 151 caregivers who were
invited to participate agreed to complete the question-
naire (response rate 98.7%). The caregivers were all
parents (Additional file 1).
The patient ages ranged from 17 months to 30 years.
Thirty-three patients were ambulant and 116 non ambu-
lant (109 type 2 and 7 type 3).
When asked to describe the patients’ clinical course
over the last year, 15% reported stability, 72% deterior-
ation and 12% improvement.
When asked what to expect in the next 2 years, 21%
anticipated a stable course, 70% a deterioration and 9%
an improvement. Figure 1 summarizes the distribution
of findings for both questions.
When asked to summarize their expectations regard-
ing clinical trials, 72% of the caregivers would participate
if the treatment slowed down deterioration, 88% if it
Pera et al. BMC Neurology  (2017) 17:39 Page 3 of 10
Table 1 Details of the caregivers and patients’ responses in the 4 focus groups
HMFSE Item HMFSE activities Answers Group 1 Group 2 Group 3 Group 4
1 Able to sit on chair or with legs off
bed with or without hand support
Sitting on normal school chair or public
spaces (stools in restaurant)
● ● ● ●
Sitting on toilet ● ● ●
Sitting in car ●
Independence out of the house ● ●
Dress by herself/himself ●
2 Able to sit on floor cross legged or
legs stretched in front
Play on floor with siblings ● ● ● ●
Sit on lounge chair, deck-chair ● ●
Picnic ● ●
Travel with less equipment ●
Inclusion in activities ●
3 Able to bring hands to face at eye level Wash face ● ● ● ●
Brush and style ● ● ● ●
Eat ● ●
Put on eye glasses ● ● ●
Answer telephone ●
Blow nose ●
4 Able to bring hands to head Scratch head ● ● ● ●
Wash, brush, style hair ● ● ●
Put on hat ● ● ●
Dress upper body ● ●
5 Roll to side Sleep by myself in my own room ● ●
Caregiver does not have to wake up to
turn him/her
● ● ●
Help during dressing lying down ● ●
Not having to turn head to see ●
6-7-8-9 Roll Play ● ●
Sleep well ● ●
Sunbathe ● ●
Experience space ● ●
Reach for something at sides when
lying down
● ●
10 Able to lye down from sitting Independence: lye down and rest
when tired
● ● ● ●
Fun movement when falling ● ●
Rest on the back ●
Safety: Fall in a controlled way (avoid
head trauma)
●
11 Able to raise head when lying prone Turn head react to stimulus, visual
exploration of surroundings
● ● ●
Read a book ● ● ●
Not be afraid of choking ●
Watch TV ● ●
On beach not get sand in face ●
12-13 Able to prop on forearms or extend arms Read a book ● ● ●
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Table 1 Details of the caregivers and patients’ responses in the 4 focus groups (Continued)
Watch TV ● ● ●
Stretch back ●
Sun bathe ●
14 Able to sit up from lying No need for assistant ● ● ●
Wake up and not have to wait for someone
to sit me up
● ● ● ●
Independence ● ●
Sit up and drink at night ● ●
15 Able to four-point kneel Play like an animal in school ● ● ●
Hiding ●
Be able to fit under small spaces ●
16 Able to crawl Move around ● ● ● ●
Experience space ● ●
Go get objects ● ●
Play on floor ● ●
17 Lift head from supine Change head position ● ● ●
Drink at night ● ●
Read ●
Watch TV ●
Check the clock or alarm ●
18 Stand with support Use toilet standing (boy) ● ● ●
Use full length mirror, perceive body
dimensions and proportions
● ●
Shower properly ●
Climb in car ●
Use kitchen burners, cook ●
19 Stand without support Public spaces: wait for bus, stand in cue ●
Cook ●
Use normal sink ●
Dress ●
Reach something on a shelf ●
20 Able to walk Freedom ● ● ●
Go where and when you please ● ● ●
Get to places ● ● ●
Not to have to rely on wheelchair batteries ●
21-22 Able to flex hip from supine Dress (pants, socks) ● ● ● ●
Scratch legs, kill mosquito ● ●
Change position ●
23-24-25-26 Able to half kneel Pick up object on floor ● ●
Tie shoe laces ● ●
Put away object on low surfaces ●
Pet a dog ●
Play ●
Make a proposal ●
Kneel in church ●
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would stop deterioration and 97% if the treatment
produced an improvement.
When we correlated the responses to the functional
status of the patients, the percentage of caregivers will-
ing to take part in a clinical trial, if the treatment was
expected to slow down deterioration, was higher in the
non-ambulant group (76%) than in the ambulant group
(61%) even though the difference was not significant
(p > 0.05) (Figure 2 and 3).
When asked, after being informed of the next three
items that their child could not achieve on the HFMSE
scale, if achieving at least one of these abilities completely
(score 2) would justify their participation in a clinical trial,
75% would consider taking part if they could achieve at
least one of these abilities, 89% if they could achieve 2 and
100% if they could achieve more than 2. The results were
widely distributed across functional levels and age. The
correlation between the responses and the functional
scores was not significant (p > 0.05).
The percentage of caregivers considered participating
in a clinical trial if their child might achieve one activity
was not significantly different among the ambulant and
Table 1 Details of the caregivers and patients’ responses in the 4 focus groups (Continued)
Talk with a kid ●
27 Able to go from standing to sitting Not get hurt when falling or not fall in
an embarrassing way
● ●
Sit on grass or sand ● ● ●
Pet a dog ●
Sit beside a friend in same position/play
on floor
● ●
Pick up something from floor ● ●
28 Able to squat Sit when needed ● ●
Pick up objects on floor ● ● ●
Pee ● ●
Tie shoes ●
Pull up trousers ●
29 Able to jump Have fun, play ● ● ● ●
Dance, gymnastics ● ●
Avoid obstacles ● ● ●
Normality ● ●
Go to friends’ home regardless of where
they live
● ● ●
Stay and live in my own home ●
30-31-32-33 Go up and down stairs Absence of barriers ● ● ● ●
Normality ● ●
Go to friends’ home regardless of where
they live
● ● ●
Stay and live in my own home ●
Fig. 1 Individual responses plotted against age in non-ambulant (gray circle) and ambulant (▲) patients
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non ambulant groups (p > 0.005), a list of of the most
frequent activities that caregivers hope will be achieved
is provided in Table 2. The results were widely distrib-
uted across functional levels and age (Fig. 4).
Discussion
The results of our first study, assessing content validity,
confirm that the activities of the HFMSE, known to be
relevant both in clinical and research practice, are also
clinically meaningful to patients and their caregivers.
Following the FDA guidelines [18], we used a question-
naire exploring all items and a structured qualitative
interview as part of focus groups, in a cohort of patients
and caregivers that included both genders, patients of
different ages, and SMA patients who represent the full
range of motor function captured on the HFMSE. The
analysis of the transcripts of the focus groups demon-
strated that each activity included in the HFMSE was re-
lated to activities of daily living that were relevant to
patients and their caregivers, as often suggested by
many participants in more than one focus group. The
group including patients had similar responses to the
other 3 groups, only including parents, for 101 of the
103 responses provided. Each of the items and the
explored domains were thought to be appropriate for
use in SMA.
Fig. 2 Individual responses to the question: ‘Would you agree to have your child take part in a potential trial if, in the absence of side-effects or
with possible minimal side-effects, the prospect was to slow down a possible decline in motor function for at least two years?’
Fig. 3 Individual responses to the same question as in fig. 2. Responses are plotted against functional level for non ambulant (gray circle) and
ambulant (▲) patients. Functional level is defined both using the raw HFMSE scores and the classification expressing severity in decimals, starting
from 2.1, for patients who are just able to sit, to the strongest type 2, 2, who are able to stand but not to walk, to the type 3 [1]
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Not surprisingly, as also demonstrated in the second
part of our study, the responses of patients and care-
givers showed a degree of heterogeneity. This can be
easily explained by the fact that the patients included in
our study had a wide age range, from infants below age
2 years to adults in their thirties, and variable functional
levels, from very weak patients with a HFMSE score of 0
who could only sit very briefly to strong ambulant
patients who achieved the highest scores on the scale. It
is, therefore, expected that the responses of individual
patients/caregivers focused on the activities that were
most challenging for them/their child, according to their
respective functional levels.
In the second part of our study we also explored the
perception of the families regarding their child’s disease
course with respect to motor function. The majority (72%)
felt that over the last year their child had deterioration,
whereas 15% reported a stabilization. The remaining 12%
reported an improvement, and this occurred mainly in the
younger end of the cohort. These results are in agreement
with our recent collaborative study showing that a clinical
improvement could be detected mainly in young
children up to age 6 years as documented on the
HFMSE. Clinical deterioration was more likely to
occur around puberty [10].
As a result, over 70% of the caregivers felt that they
would consider participating in a clinical trial if, in the ab-
sence of significant side effects, the intervention would
slow down the rate of deterioration. Not surprisingly there
were even higher percentages of caregivers considering
participating in a trial if the prospect was stabilization
(88%) or improvement (97%). These results should be
interpreted with caution as considering participation in a
clinical trial is complex and not all the studies have the
same demands or the same possible outcomes. Neverthe-
less, these findings are already, in and of themselves,
strongly indicative that caregivers would consider a trial
even if the prospect was limited to influencing the rate of
deterioration regardless of age or functional level.
In the second part of this study we tried to explore, in
further detail, whether achieving or maintaining
activities on the HFMSE had the same relevance regard-
less of HFMSE scores and, therefore, different functional
levels.
The advantage of this approach is that the caregivers
could relate the questions to the actual status of the
child and were asked questions about activities that were
realistically close to their child’s possible achievements
rather than generic questions on activities, such as walk-
ing or running that would be highly desirable but, at
least in a limited time frame, difficult or impossible to
achieve especially for the weakest patients. When asked
if they would consider taking part in a trial if there was
the possibility of achieving one, two, or more than two
activities, 75% considered participation even if just one
activity was achieved. These results were widely distrib-
uted across functional levels and age.
Conclusions
These findings suggest that even if the achievable activ-
ities are different, any improvement is considered to be
meaningful, regardless as to whether the baseline score
Fig. 4 Individual responses plotted against age and functional level in non-ambulant (gray cirlce) and ambulant (▲) patients
Table 2 Details of the most frequent activities that caregivers
hope will be achieved
Activities to achieve % Activities to achieve %
Strength in the upper limbs 15,7% Stand up from a chair 2,5%
Rolling 9,0% Stand up from floor 2,5%
Walking 7,1% Respiratory function 2,2%
Standing independently 6,2% Writing skills 2,2%
Strength of the head 5,6% Run 1,9%
Personal hygiene 4,9% General autonomy 1,5%
Move independently 4,9% Crawling 1,5%
Do stairs 4,6% Hop/Jump 1,5%
Eat independently 3,1% Strength of the hands 1,5%
Sit independently 3,1% Use manual wheel-chair 1,2%
Strength in the lower limbs 2,8% Balance 1,2%
Strength of the trunk 2,8% Standing with support 1,2%
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is very low, in the middle, or very high. This conclusion
is particularly important considering the fact that the or-
dinal nature of the scale makes this comparison difficult.
This study has several limitations; first, the number of
patients was relatively small but the range of age and
functional level was quite wide and representative of the
ambulant and non-ambulant SMA population. Since the
Italian and English versions of the questionnaire’s data
collection sheet, and the forms used to illustrate the
items with pictures from the scale manual, were piloted
and validated before their use, these findings can justify
another follow-on study with a larger cohort.
All the patients were followed in tertiary care centers
or were part of advocacy groups and were unlikely to be
representative of a more general population. While this
is a potential bias, these patients are more likely to be
representative of a trial population with appropriate
standards of care and level of information and participa-
tion. Another apparent limitation is the fact that, in the
second part of the study, we only involved caregivers.
This was, however, necessary in order to include patients
of all ages; very young patients would have not been able
to complete the questionnaires. We acknowledge that
the patient’s perspective is however very important and
further studies are in progress to collect data directly
from patients who are older than age 12 years.
Despite these limitations, the study results support
the use of the HFMSE as a robust outcome measure
in clinical trials, not only because all the individual
items appear to be meaningful to patients and care-
givers, but also because even small changes detected
on the scale appear to be relevant and to justify
participation in a clinical trial. The great majority of
the caregivers would already consider participation of
their children in a clinical study even if the best
outcome would be just to reduce deterioration. Of
course, even more caregivers would agree to their
child’s participation if the prospect was to remain
stable or improve; however, it is of interest that even
when aiming for an improvement, a small improve-
ment (just one activity) would already be sufficient in
their mind to justify participation in a trial with an
investigational drug.
Finally, these results are important as they provide the
views of patients and caregivers and complement other
studies currently being performed and designed to estab-
lish item response theory approach and the minimally
important difference using statistical analysis.
Additional file
Additional file 1: Questionnaire provided to the carers. Sample of the
questionnaire submitted to the carers. (DOCX 19 kb)
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